AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +178.3%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Debt to equity
AxoGen, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.5× from fiscal 2025 (0.5×). Over the past ten years it has ranged from 0.0× (fiscal 2018) to 3.0× (fiscal 2015); the current reading is higher than 36% of that period. That is in line with the Medical Devices industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.5× | (20.59%) |
| FY2024 | 0.7× | (6.65%) |
| FY2023 | 0.7× | 6.07% |
| FY2022 | 0.7× | 11.40% |
| FY2021 | 0.6× | 37.27% |
| FY2020 | 0.4× | 1,632.54% |
| FY2019 | 0.0× | 3,050.00% |
| FY2018 | 0.0× | (99.92%) |
| FY2017 | 1.0× | (39.93%) |
| FY2016 | 1.6× | (45.94%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | (49.58%) |
| Jun 2026 | 0.1× | (16.25%) |
| Mar 2026 | 0.1× | (83.94%) |
| Dec 2025 | 0.5× | (3.30%) |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| INSP Inspire Medical Systems, Inc. compare | 0.0× |
| ALMR Alamar Biosciences, Inc. compare | 0.0× |
| AXGN AxoGen, Inc. | 0.0× |
| TMDX TransMedics Group, Inc. compare | 0.1× |
| UFPT UFP Technologies, Inc. compare | 0.2× |
| NEOG Neogen Corporation compare | 0.4× |
| ITGR Integer Holdings Corporation compare | 0.7× |
| IRTC iRhythm Holdings, Inc. compare | 3.7× |
| ESTA Establishment Labs Holdings Inc. compare | 12.1× |
| Medical Devices industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement